- Revenue of $675 million; (30)% reported growth; (27)%
organic growth; 6% non-COVID organic growth
- GAAP EPS of $4.50; Adjusted EPS from continuing operations
of $1.01
- Updates full year 2023 guidance
- Authorizes new $600 million share repurchase
program
- To begin trading under new ticker “RVTY” on May
16th
Revvity, Inc. (NYSE: PKI), today reported financial results for
the first quarter ended April 2, 2023.
The Company reported GAAP earnings per share of $4.50, as
compared to $1.40 in the same period a year ago. GAAP revenue for
the quarter was $675 million, as compared to $963 million in the
same period a year ago. GAAP operating income for the quarter was
$76 million, as compared to $262 million for the same period a year
ago. GAAP operating profit margin was 11.3% as a percentage of
revenue, as compared to 27.2% in the same period a year ago.
Adjusted earnings per share from continuing operations for the
quarter was $1.01, as compared to $2.30 in the same period a year
ago. Adjusted revenue for the quarter was $675 million, as compared
to $963 million in the same period a year ago. Adjusted operating
income was $189 million, as compared to $393 million for the same
period a year ago. Adjusted operating profit margin was 28.0% as a
percentage of adjusted revenue, as compared to 40.8% in the same
period a year ago.
Adjustments for the Company's non-GAAP financial measures have
been noted in the attached reconciliations.
“Revvity has tremendous potential as we enter this new phase of
our company’s journey,” said Prahlad Singh, president and chief
executive officer of Revvity. “Our strong first quarter results
demonstrate our consistent and high level of execution and set us
on a positive path as we begin this next chapter in our
transformation.”
Stock Ticker Change
The Company’s stock ticker will change from PKI to RVTY with the
beginning of trading on May 16, 2023. Members of the Revvity team
will ring the opening bell of the New York Stock Exchange that
morning to commemorate the launch of the Company’s new corporate
name and brand, and to celebrate initial trading under the new
stock ticker. A livestream of the ceremony can be viewed at
www.nyse.com/bell with videos and photos from the day to be
provided on our social media channels.
Financial Overview by Reporting Segment for the First
Quarter
Life Sciences
- First quarter 2023 revenue was $328 million, as compared to
$306 million in the same period a year ago. Reported revenue
increased 7% and organic revenue increased 9% as compared to the
same period a year ago.
- First quarter 2023 adjusted operating income was $129 million,
as compared to $110 million in the same period a year ago.
- First quarter 2023 adjusted operating profit margin was 39.4%
as a percentage of adjusted revenue, as compared to 36.0% in the
same period a year ago.
Diagnostics
- First quarter 2023 revenue was $347 million, as compared to
$657 million in the same period a year ago. Reported revenue
decreased 47% and organic revenue decreased 44% as compared to the
same period a year ago.
- First quarter 2023 adjusted operating income was $74 million,
as compared to $301 million in the same period a year ago.
- First quarter 2023 adjusted operating profit margin was 21.5%
as a percentage of adjusted revenue, as compared to 45.8% in the
same period a year ago.
Updates Full Year 2023 Guidance
For the full year 2023, the Company now forecasts total revenue
of $2.90-$2.94 billion and adjusted earnings per share of
$4.85-$5.05. This guidance assumes no additional contribution from
COVID related revenues.
Guidance for the full year 2023 is provided on a non-GAAP basis
and cannot be reconciled to the closest GAAP measures without
unreasonable effort due to the unpredictability of the amounts and
timing of events affecting the items the Company excludes from
these non-GAAP measures. The timing and amounts of such events and
items could be material to the Company’s results prepared in
accordance with GAAP.
Webcast Information
The Company will discuss its first quarter 2023 results and its
outlook for business trends during a webcast on May 11, 2023, at
8:00 a.m. Eastern Time. A live audio webcast and presentation will
be available on the Investors section of the Company’s website,
ir.revvity.com.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with
generally accepted accounting principles (GAAP), this earnings
announcement also contains non-GAAP financial measures. The reasons
that we use these measures, a reconciliation of these measures to
the most directly comparable GAAP measures, and other information
relating to these measures are included below following our GAAP
financial statements.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements relating to
estimates and projections of future earnings per share, cash flow
and revenue growth and other financial results, developments
relating to our customers and end-markets, and plans concerning
business development opportunities, acquisitions and divestitures.
Words such as "believes," "intends," "anticipates," "plans,"
"expects," “estimates”, "projects," "forecasts," "will" and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on
management's current assumptions and expectations and no assurances
can be given that our assumptions or expectations will prove to be
correct. A number of important risk factors could cause actual
results to differ materially from the results described, implied or
projected in any forward-looking statements. These factors include,
without limitation: (1) markets into which we sell our products
declining or not growing as anticipated; (2) the effect of the
COVID-19 pandemic on our sales and operations; (3) fluctuations in
the global economic and political environments; (4) our failure to
introduce new products in a timely manner; (5) our ability to
execute acquisitions and divestitures, license technologies, or to
successfully integrate acquired businesses and licensed
technologies into our existing business or to make them profitable,
or successfully divest businesses; (6) our ability to compete
effectively; (7) fluctuation in our quarterly operating results and
our ability to adjust our operations to address unexpected changes;
(8) significant disruption in third-party package delivery and
import/export services or significant increases in prices for those
services; (9) disruptions in the supply of raw materials and
supplies; (10) our ability to retain key personnel; (11)
significant disruption in our information technology systems, or
cybercrime; (12) our ability to realize the full value of our
intangible assets; (13) our failure to adequately protect our
intellectual property; (14) the loss of any of our licenses or
licensed rights; (15) the manufacture and sale of products exposing
us to product liability claims; (16) our failure to maintain
compliance with applicable government regulations; (17) regulatory
changes; (18) our failure to comply with healthcare industry
regulations; (19) economic, political and other risks associated
with foreign operations; (20) our ability to obtain future
financing; (21) restrictions in our credit agreements; (22)
significant fluctuations in our stock price; (23) reduction or
elimination of dividends on our common stock; and (24) other
factors which we describe under the caption "Risk Factors" in our
most recent annual report on Form 10-K and in our other filings
with the Securities and Exchange Commission. We disclaim any
intention or obligation to update any forward-looking statements as
a result of developments occurring after the date of this press
release.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is
a call to action. Revvity provides health science solutions,
technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with
specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection
and diagnosis, informatics and more.
With more than $3 billion in revenue and over 11,000 employees,
Revvity serves customers across pharmaceutical and biotech,
diagnostic labs, academia and governments. It is part of the
S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, Twitter,
YouTube, Facebook and Instagram for updates.
Revvity, Inc. and Subsidiaries CONDENSED CONSOLIDATED
INCOME STATEMENTS
Three
Months Ended
(In thousands, except per share data) April 2, 2023 April
3, 2022 Revenue
$
674,865
$
963,163
Cost of revenue
293,499
368,423
Selling, general and administrative expenses
248,557
275,260
Research and development expenses
56,690
57,524
Operating income from continuing operations
76,119
261,956
Interest income
(5,272
)
(595
)
Interest expense
22,738
28,388
Change in fair value of financial securities
(2,768
)
12,124
Other expense (income), net
31,981
(2,865
)
Income from continuing operations, before income taxes
29,440
224,904
Provision for income taxes
4,595
40,834
Income from continuing operations
24,845
184,070
Income (loss) from discontinued operations
544,630
(7,108
)
Net income
$
569,475
$
176,962
Diluted earnings per share: Income from
continuing operations
$
0.20
$
1.45
Income (loss) from discontinued operations
4.31
(0.06
)
Net income
$
4.50
$
1.40
Weighted average diluted shares of common stock outstanding
126,469
126,635
ABOVE PREPARED IN ACCORDANCE WITH GAAP
Additional
supplemental information (1): (per share, continuing
operations) GAAP EPS from continuing operations
$
0.20
$
1.45
Amortization of intangible assets
0.73
0.75
Debt extinguishment costs
(0.03
)
0.00
Purchase accounting adjustments
(0.01
)
0.14
Acquisition and divestiture-related costs
0.35
0.07
Change in fair value of financial securities
(0.02
)
0.10
Significant litigation matters and settlements
-
0.00
Significant environmental matters
0.01
-
Restructuring and other, net
0.02
0.07
Tax on above items
(0.23
)
(0.28
)
Significant tax items
(0.01
)
-
Adjusted EPS from continuing operations
$
1.01
$
2.30
(1) amounts may not sum due to rounding Revvity,
Inc. and Subsidiaries REVENUE AND OPERATING INCOME
(LOSS) Three Months
Ended (In thousands, except percentages)
April 2, 2023 April 3, 2022 Adjusted revenue and
operating income Reported revenue
$
674,865
$
963,163
Revenue purchase accounting adjustments
206
203
Adjusted revenue
675,071
963,366
Reported operating income from continued operations
76,119
261,956
OP%
11.3
%
27.2
%
Amortization of intangible assets
91,811
95,213
Purchase accounting adjustments
(914
)
18,004
Acquisition and divestiture-related costs
17,951
8,817
Significant litigation matters and settlements
-
425
Significant environmental matters
1,132
-
Restructuring and other, net
3,095
8,983
Adjusted operating income
$
189,194
$
393,398
OP%
28.0
%
40.8
%
Segment revenue and segment operating income
Life Sciences
$
328,441
$
306,087
Diagnostics
346,630
657,279
Revenue purchase accounting adjustments
(206
)
(203
)
Reported revenue
674,865
963,163
Life Sciences
129,459
110,181
39.4
%
36.0
%
Diagnostics
74,432
300,899
21.5
%
45.8
%
Corporate
(14,697
)
(17,682
)
Subtotal reportable segments operating income
189,194
393,398
Amortization of intangible assets
(91,811
)
(95,213
)
Purchase accounting adjustments
914
(18,004
)
Acquisition and divestiture-related costs
(17,951
)
(8,817
)
Significant litigation matters and settlements
-
(425
)
Significant environmental matters
(1,132
)
-
Restructuring and other, net
(3,095
)
(8,983
)
Reported operating income from continued operations
$
76,119
$
261,956
REPORTED REVENUE AND REPORTED
OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP
Revvity, Inc. and Subsidiaries CONDENSED CONSOLIDATED
BALANCE SHEETS (In thousands)
April 2, 2023 January 1, 2023 Current assets: Cash
and cash equivalents
$
2,267,183
$
454,358
Marketable securities
193,963
-
Accounts receivable, net
586,922
612,780
Inventories, net
429,423
405,462
Other current assets
318,116
122,254
Current assets of discontinued operations
-
1,693,704
Total current assets
3,795,607
3,288,558
Property, plant and equipment, net
491,162
482,950
Operating lease right-of-use assets
167,905
188,351
Intangible assets, net
3,294,657
3,377,174
Goodwill
6,505,956
6,481,768
Other assets, net
382,868
311,054
Total assets
$
14,638,155
$
14,129,855
Current liabilities: Current portion of long-term debt
$
479,423
$
470,929
Accounts payable
266,884
272,826
Accrued expenses and other current liabilities
817,432
527,863
Current liabilities of discontinued operations
-
272,865
Total current liabilities
1,563,739
1,544,483
Long-term debt
3,880,984
3,923,347
Long-term liabilities
1,010,230
1,109,181
Operating lease liabilities
149,392
169,968
Total liabilities
6,604,345
6,746,979
Total stockholders' equity
8,033,810
7,382,876
Total liabilities and stockholders' equity
$
14,638,155
$
14,129,855
PREPARED IN ACCORDANCE WITH
GAAP
Revvity, Inc. and Subsidiaries CONSOLIDATED
STATEMENTS OF CASH FLOWS Three Months Ended April 2, 2023 April
3, 2022 (In thousands)
Operating activities: Net
income
$
569,475
$
176,962
(Income) loss from discontinued operations, net of income taxes
(544,630
)
7,108
Income from continuing operations
24,845
184,070
Adjustments to reconcile income from continuing operations to net
cash provided by continuing operations: Stock-based compensation
9,893
14,438
Restructuring and other, net
3,096
8,983
Depreciation and amortization
109,008
109,330
Change in fair value of contingent consideration
(1,360
)
693
Amortization of deferred debt financing costs and accretion of
discounts
1,792
1,781
Change in fair value of financial securities
(2,768
)
12,125
Debt extinguishment (income) loss
(3,345
)
119
Unrealized foreign exchange loss
26,095
-
Amortization of acquired inventory revaluation
-
16,868
Changes in assets and liabilities which provided (used) cash,
excluding effects from companies acquired: Accounts receivable, net
34,424
77,398
Inventories
(18,520
)
(20,943
)
Accounts payable
(4,895
)
26,739
Accrued expenses and other
(106,591
)
(105,480
)
Net cash provided by operating activities of continuing
operations
71,674
326,121
Net cash used in operating activities of discontinued
operations
(8,211
)
(42,906
)
Net cash provided by operating activities
63,463
283,215
Investing activities: Capital expenditures
(20,946
)
(26,969
)
Purchases of investments
-
(18,000
)
Purchases of marketable securities
(193,454
)
-
Cash paid for acquisitions, net of cash, cash equivalents and
restricted cash acquired
(686
)
(3,630
)
Net cash used in investing activities of continuing
operations
(215,086
)
(48,599
)
Net cash provided by (used in) investing activities of
discontinued operations
2,079,588
(7,707
)
Net cash provided by (used in) investing activities
1,864,502
(56,306
)
Financing Activities: Payments on borrowings
-
(220,000
)
Proceeds from borrowings
-
220,000
Payments of term loan
-
(100,000
)
Payments of senior debt
(49,603
)
-
Settlement of cash flow hedges
-
(762
)
Net proceeds (payments) on other credit facilities
7,867
(1,064
)
Payments for acquisition-related contingent consideration
(1,475
)
-
Proceeds from issuance of common stock under stock plans
523
1,397
Purchases of common stock
(61,656
)
(55,592
)
Dividends paid
(8,841
)
(8,837
)
Net cash used in financing activities
(113,185
)
(164,858
)
Effect of exchange rate changes on cash, cash equivalents,
and restricted cash
(16,969
)
(10,636
)
Net increase in cash, cash equivalents, and restricted
cash
1,797,811
51,415
Cash, cash equivalents, and restricted cash at beginning of period
470,746
619,337
Cash, cash equivalents, and restricted cash at end of period
$
2,268,557
$
670,752
Supplemental disclosure of cash flow
information: Reconciliation of cash, cash equivalents and
restricted cash reported within the consolidated balance sheets
that sum to the total shown in the consolidated statements of cash
flows: Cash and cash equivalents
$
2,267,183
$
654,756
Restricted cash included in other current assets
1,019
997
Restricted cash included in other assets
355
-
Cash and cash equivalents included in current assets of
discontinued operations
-
14,999
Total cash, cash equivalents and restricted cash
$
2,268,557
$
670,752
PREPARED IN ACCORDANCE WITH
GAAP
Revvity, Inc. and Subsidiaries RECONCILIATION OF GAAP TO
NON-GAAP FINANCIAL MEASURES (1) Revvity
Three Months Ended April 2,
2023 Organic revenue growth: Reported revenue
growth from continuing operations
-30%
Less: effect of foreign exchange rates
-3%
Less: effect of acquisitions including purchase accounting
adjustments and impact of divested businesses
0%
Organic revenue growth from continuing operations
-27%
Less: effect of COVID products
-33%
Non-COVID organic revenue growth from continuing operations
6%
Life Sciences Three Months Ended
April 2, 2023 Organic
revenue growth: Reported revenue growth from continuing
operations
7%
Less: effect of foreign exchange rates
-2%
Less: effect of acquisitions including purchase accounting
adjustments and impact of divested businesses
0%
Organic revenue growth from continuing operations
9%
Diagnostics Three Months Ended
April 2, 2023 Organic
revenue growth: Reported revenue growth from continuing
operations
-47%
Less: effect of foreign exchange rates
-3%
Less: effect of acquisitions including purchase accounting
adjustments and impact of divested businesses
0%
Organic revenue growth from continuing operations
-44%
Less: effect of COVID products
-47%
Non-COVID organic revenue growth from continuing operations
3%
(1) amounts may not sum due to rounding
Explanation of Non-GAAP Financial Measures
We report our financial results in accordance with GAAP.
However, management believes that, in order to more fully
understand our short-term and long-term financial and operational
trends, investors may wish to consider the impact of certain
non-cash, non-recurring or other items, which result from facts and
circumstances that vary in frequency and impact on continuing
operations. Accordingly, we present non-GAAP financial measures as
a supplement to the financial measures we present in accordance
with GAAP. These non-GAAP financial measures provide management
with additional means to understand and evaluate the operating
results and trends in our ongoing business by adjusting for certain
non-cash expenses and other items that management believes might
otherwise make comparisons of our ongoing business with prior
periods more difficult, obscure trends in ongoing operations, or
reduce management's ability to make useful forecasts. Management
believes these non-GAAP financial measures provide additional means
of evaluating period-over-period operating performance. In
addition, management understands that some investors and financial
analysts find this information helpful in analyzing our financial
and operational performance and comparing this performance to our
peers and competitors.
We use the term “adjusted revenue” to refer to GAAP revenue,
including purchase accounting adjustments for revenue from
contracts acquired in acquisitions that will not be fully
recognized due to accounting rules. We use the related term
“adjusted revenue growth” to refer to the measure of comparing
current period adjusted revenue with the corresponding period of
the prior year.
We use the term “organic revenue” to refer to GAAP revenue,
excluding the effect of foreign currency changes and revenue from
recent acquisitions and divestitures and including purchase
accounting adjustments for revenue from contracts acquired in
acquisitions that will not be fully recognized due to accounting
rules. We use the related term “organic revenue growth” to refer to
the measure of comparing current period organic revenue with the
corresponding period of the prior year. We use the related term
“non-COVID organic revenue growth” to refer to the measure of
comparing current period organic revenue excluding revenue from
COVID related products and services with the corresponding period
of the prior year excluding revenue from COVID related products and
services.
We use the term “adjusted gross margin” to refer to GAAP gross
margin, excluding amortization of intangible assets and inventory
fair value adjustments related to business acquisitions, asset
impairments, and including purchase accounting adjustments for
revenue from contracts acquired in acquisitions that will not be
fully recognized due to business combination accounting rules. We
use the related term “adjusted gross margin percentage” to refer to
adjusted gross margin as a percentage of adjusted revenue.
We use the term “adjusted SG&A expense” to refer to GAAP
SG&A expense, excluding amortization of intangible assets,
purchase accounting adjustments, acquisition and
divestiture-related expenses, significant litigation matters and
settlements, asset impairments, and significant environmental
charges. We use the related term “adjusted SG&A percentage” to
refer to adjusted SG&A expense as a percentage of adjusted
revenue.
We use the term “adjusted R&D expense” to refer to GAAP
R&D expense, excluding amortization of intangible assets and
purchase accounting adjustments. We use the related term “adjusted
R&D percentage” to refer to adjusted R&D expense as a
percentage of adjusted revenue.
We use the term “adjusted net interest and other expense” to
refer to GAAP net interest and other expense, excluding adjustments
for mark-to-market accounting on post-retirement benefits, changes
in foreign exchange associated with acquisitions and divestitures,
changes in the value of financial securities and debt
extinguishment costs.
We use the term “adjusted operating income,” to refer to GAAP
operating income, including revenue from contracts acquired in
acquisitions that will not be fully recognized due to accounting
rules, and excluding amortization of intangible assets, other
purchase accounting adjustments, acquisition and
divestiture-related expenses, significant litigation matters and
settlements, significant environmental charges, asset impairments,
and restructuring and other charges. We use the related terms
“adjusted operating profit percentage,” “adjusted operating profit
margin,” or “adjusted operating margin” to refer to adjusted
operating income as a percentage of adjusted revenue.
We use the term “adjusted earnings per share,” or “adjusted
EPS,” to refer to GAAP earnings per share, including revenue from
contracts acquired in acquisitions that will not be fully
recognized due to accounting rules, and excluding discontinued
operations, amortization of intangible assets, debt extinguishment
costs, other purchase accounting adjustments, acquisition and
divestiture-related expenses, significant litigation matters and
settlements, significant environmental charges, changes in the
value of financial securities, disposition of businesses and
assets, net, changes in foreign exchange associated with
acquisitions and divestitures, asset impairments and restructuring
and other charges. We also exclude adjustments for mark-to-market
accounting on post-retirement benefits, therefore only our
projected costs have been used to calculate this non-GAAP measure.
We also adjust for any tax impact related to the above items and
exclude the impact of significant tax events.
We use the term “adjusted earnings per share from continuing
operations,” to refer to GAAP earnings per share from continuing
operations, including revenue from contracts acquired in
acquisitions that will not be fully recognized due to accounting
rules, amortization of intangible assets, debt extinguishment
costs, other purchase accounting adjustments, acquisition and
divestiture-related expenses, significant litigation matters and
settlements, significant environmental charges, changes in the
value of financial securities, disposition of businesses and
assets, net, changes in foreign exchange associated with
acquisitions and divestitures, asset impairments and restructuring
and other charges. We also exclude adjustments for mark-to-market
accounting on post-retirement benefits, therefore only our
projected costs have been used to calculate this non-GAAP measure.
We also adjust for any tax impact related to the above items and
exclude the impact of significant tax events.
Management includes or excludes the effect of each of the items
identified below in the applicable non-GAAP financial measure
referenced above for the reasons set forth below with respect to
that item:
- Amortization of intangible assets—
purchased intangible assets are amortized over their estimated
useful lives and generally cannot be changed or influenced by
management after the acquisition. Accordingly, this item is not
considered by management in making operating decisions. Management
does not believe such charges accurately reflect the performance of
our ongoing operations for the period in which such charges are
incurred.
- Debt extinguishment costs—we incur
costs and income related to the extinguishment of debt; including
make-whole payments to debt holders, accelerated amortization of
debt fees and discounts, and expense or income from hedges to lock
in make-whole payments. We exclude the impact of these items from
our non-GAAP measures because we believe they do not reflect the
performance of our ongoing operations.
- Revenue from contracts acquired in
acquisitions that will not be fully recognized due to accounting
rules— accounting rules require us to account for the fair
value of revenue from contracts assumed in connection with our
acquisitions. As a result, our GAAP results reflect the fair value
of those revenues, which is not the same as the revenue that
otherwise would have been recorded by the acquired entity. We
include such revenue in our non-GAAP measures because we believe
the fair value of such revenue does not accurately reflect the
performance of our ongoing operations for the period in which such
revenue is recorded.
- Other purchase accounting
adjustments—accounting rules require us to adjust various
balance sheet accounts, including inventory, fixed assets and
deferred rent balances to fair value at the time of the
acquisition. As a result, the expenses for these items in our GAAP
results are not the same as what would have been recorded by the
acquired entity. Accounting rules also require us to estimate the
fair value of contingent consideration at the time of the
acquisition, and any subsequent changes to the estimate or payment
of the contingent consideration and purchase accounting adjustments
are charged to expense or income. We exclude the impact of any
changes to contingent consideration from our non-GAAP measures
because we believe these expenses or benefits do not accurately
reflect the performance of our ongoing operations for the period in
which such expenses or benefits are recorded.
- Acquisition and divestiture-related
expenses—we incur legal, due diligence, stay bonuses,
incentive awards, stock-based compensation, interest expense,
foreign exchange gains and losses, integration expenses and other
costs related to acquisitions and divestitures. We exclude these
expenses from our non-GAAP measures because we believe they do not
reflect the performance of our ongoing operations.
- Asset impairments—we incur expense
related to asset impairments. Management does not believe such
charges accurately reflect the performance of our ongoing
operations for the periods in which such charges were
incurred.
- Restructuring and other
charges—restructuring and other charges consist of employee
severance, other exit costs as well as the cost of terminating
certain lease agreements or contracts as well as costs associated
with relocating facilities. Management does not believe such costs
accurately reflect the performance of our ongoing operations for
the period in which such costs are reported.
- Adjustments for mark-to-market accounting
on post-retirement benefits—we exclude adjustments for
mark-to-market accounting on post-retirement benefits, and
therefore only our projected costs are used to calculate our
non-GAAP measures. We exclude these adjustments because they do not
represent what we believe our investors consider to be costs of
producing our products, investments in technology and production,
and costs to support our internal operating structure.
- Significant litigation matters and
settlements—we incur expenses related to significant
litigation matters, including the costs to settle or resolve
various claims and legal proceedings. Management does not believe
such charges accurately reflect the performance of our ongoing
operations for the periods in which such charges were
incurred.
- Significant environmental
charges—we incur expenses related to significant
environmental charges. Management does not believe such charges
accurately reflect the performance of our ongoing operations for
the periods in which such charges were incurred.
- Disposition of businesses and assets,
net—we exclude the impact of gains or losses from the
disposition of businesses and assets from our adjusted earnings per
share. Management does not believe such gains or losses accurately
reflect the performance of our ongoing operations for the period in
which such gains or losses are reported.
- Impact of foreign currency changes on the
current period— we exclude the impact of foreign currency
associated with acquisitions and divestitures from these measures
by using the prior period’s foreign currency exchange rates for the
current period because foreign currency exchange rates are subject
to volatility and can obscure underlying trends.
- Impact of significant tax
events—we exclude the impact of significant tax events, such
as the Tax Cuts and Jobs Act of 2017. Management does not believe
the impact of significant tax events accurately reflects the
performance of our ongoing operations for the periods in which the
impact of such events was recorded.
- Changes in value of financial
securities—we exclude the impact of changes in the value of
financial securities. Management does not believe such gains or
losses accurately reflect the performance of our ongoing operations
for the period in which such gains or losses are reported.
- Depreciation of fixed assets ceased upon
reporting the business as held for sale—we exclude the
impact of ceasing depreciation of fixed assets that are held for
sale. Management does not believe such charges accurately reflect
the performance of our ongoing operations for the periods in which
such expenses were ceased.
# # #
The tax effect for discontinued operations is calculated based
on the authoritative guidance in the Financial Accounting Standards
Board’s Accounting Standards Codification 740, Income Taxes. The
tax effect for amortization of intangible assets, inventory fair
value adjustments related to business acquisitions, changes to the
fair values assigned to contingent consideration, debt
extinguishment costs, other costs related to business acquisitions
and divestitures, significant litigation matters and settlements,
significant environmental charges, changes in the fair value of
financial securities, adjustments for mark-to-market accounting on
post-retirement benefits, disposition of businesses and assets,
net, restructuring and other charges, and the revenue from
contracts acquired with various acquisitions is calculated based on
operational results and applicable jurisdictional law, which
contemplates tax rates currently in effect to determine our tax
provision. The tax effect for the impact from foreign currency
exchange rates on the current period is calculated based on the
average rate currently in effect to determine our tax
provision.
The non-GAAP financial measures described above are not meant to
be considered superior to, or a substitute for, our financial
statements prepared in accordance with GAAP. There are material
limitations associated with non-GAAP financial measures because
they exclude charges that have an effect on our reported results
and, therefore, should not be relied upon as the sole financial
measures by which to evaluate our financial results. Management
compensates and believes that investors should compensate for these
limitations by viewing the non-GAAP financial measures in
conjunction with the GAAP financial measures. In addition, the
non-GAAP financial measures included in this earnings announcement
may be different from, and therefore may not be comparable to,
similar measures used by other companies.
Each of the non-GAAP financial measures listed above is also
used by our management to evaluate our operating performance,
communicate our financial results to our Board of Directors,
benchmark our results against our historical performance and the
performance of our peers, evaluate investment opportunities
including acquisitions and discontinued operations, and determine
the bonus payments for senior management and employees.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230511005092/en/
Investor Relations: Steve Willoughby (781) 663-5677
steve.willoughby@revvity.com
Media Contact: Fara Goldberg (781) 663-5699
fara.goldberg@revvity.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From May 2024 to Jun 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Jun 2023 to Jun 2024